Adverse events in volunteers participating in phase I clinical trials: A single-center five-year survey in 1,559 subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 5, 2005, Pages 217-226

  Lutfullin, A ^a   Kuhlmann, J ^a   Wensing, Georg ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Adverse events; Healthy volunteers; Phase I studies

Indexed keywords

ADRENALIN; ANTIINFECTIVE AGENT; CORTICOSTEROID; DRUG; PLACEBO;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; ELBOW INJURY; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HEMORRHOID; HUMAN; HUMAN EXPERIMENT; INCIDENCE; INTERVERTEBRAL DISK HERNIA; KIDNEY COLIC; LABORATORY TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG DOSE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROTOXICITY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RESPIRATORY TRACT DISEASE; SENSORY DYSFUNCTION; SHOCK; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; THROMBOPHLEBITIS; TINNITUS; TOOTH PAIN; VOLUNTEER;

EID: 18744402166     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43217     Document Type: Article

References (19)

1. Anonymous 1985 Death of a volunteer. Br Med J 290: 1359-1370
2. Apseloff G, Ashton HM, Friedman H, Gerber N 1994 The importance of measuring of nicotine levels to identify smokers in clinical trials. Clin Pharmacol Ther 56: 460-462
3. Darragh A, Lambe R, Kenny M, Brick I 1985 Sudden death of a volunteer. Lancet 1: 93-94
4. Gauler Th, Weihrauch ThR 1997 Placebo - ein wirk-sames und ungefährliches Medikament? Urban und Schwarzenberg, München
5. Hamacher A 1984 Placebo-Nebenwirkungen bei jungen und alten hospitalisierten Personen. Inauguraldissertation, Erlangen-Nürnberg
6. ICH harmonized tripartite guideline for good clinical practice 1996
7. Kolata GB 1980 The death of a research subject. The Hastings Centre 10: 5-6
8. Kuhlmann J 2000 Clinical-pharmacological aspects of drug evaluation. In: Sirtori C, Kuhlmann J, Tillement JP, Vrhovac B (eds) Clinical Pharmacology. MacGraw-Hill, New York, pp 75-82
9. Lewis MA, Kühl-Habich D, Von Rosen J 2001 Drug use and adverse event monitoring in German children. Int J Clin Pharmacol Ther 39: 507-512
10. Monka M, Voß W 2002 Statistik am PC. Hanser, München
11. Nony P, Boissel JP, Girard P, Lion L, Haugh MC, Fareh S, De Breyene B 1994 The role of an initial single-blind placebo period in phase I clinical trials. Fundam Clin Pharmacol 8: 185-187
12. Purkins L, Love ER, Eve MD, Wooldridge CL, Cowan C, Smart TS, Johnson PJ, Rapeport WG 2003 The influence of diet on liver function tests and serum lipids in healthy male volunteers resident in a phase I unit. Br J Clin Pharmacol 57: 199-208
13. Pütz M, Kern U, Gundert-Remy U 1992 Is there an influence of the active treatment on the side effect profile of placebo in controlled clinical trials? Dtsch Ges Pharmakol Toxikol C 47: 346
14. Reidenberg NN, Lowenthal DT 1968 Adverse non-drug reactions. N Engl J Med 279: 678-679
15. Rosenzweig P, Brohier S, Zipfel A 1993 The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clin Pharmacol Ther 54: 578-583
16. Sibille M, Deigat N, Jannin A, Kirkesseli S, Vital Durand D 1998 Adverse events in phase I studies: a report in 1015 healthy volunteers. Eur J Clin Pharmacol 54: 13-20
17. Silverman K, Evans SM, Strain EC, Grifiths RR 1992 Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 327: 1109-1114
18. Trigg CJ, Freestone DS, Lee TH, Mant TGK 1998 Death of a healthy student volunteer in a US research study: lessons for bronchoscopic practice. Int J Pharm Med 12: 151-153
19. Zarofonetis D, Riley PA, Willis PW, Power LH, Werbelow J, Farhat L, Beckwith W, Marks BH 1978 Clinically significant adverse effects in a phase I testing program. Clin Pharmacol Ther 24: 127-132